Enlivex Therapeutics Secures $5M Private Placement
Ticker: ENLV · Form: 6-K · Filed: May 28, 2024 · CIK: 1596812
Sentiment: neutral
Topics: private-placement, financing, healthcare
TL;DR
Enlivex raises $5M via private placement at $3.25/share, closing early June.
AI Summary
On May 28, 2024, Enlivex Therapeutics Ltd. announced a definitive agreement with a single healthcare-focused institutional investor for a private placement. The company will issue approximately 1,538,462 ordinary shares at a purchase price of $3.25 per share, expected to close on or about June 4, 2024, raising gross proceeds of approximately $5 million.
Why It Matters
This capital infusion provides Enlivex with additional funding to advance its clinical programs, potentially accelerating drug development and market entry.
Risk Assessment
Risk Level: medium — The company is raising capital through a private placement, which can dilute existing shareholders and indicates a need for funding to advance its operations.
Key Numbers
- $5.0M — Gross Proceeds (Raised from private placement)
- $3.25 — Share Price (Purchase price in private placement)
- 1,538,462 — Shares Issued (Number of ordinary shares in private placement)
Key Players & Entities
- Enlivex Therapeutics Ltd. (company) — Registrant
- May 28, 2024 (date) — Announcement date
- healthcare-focused institutional investor (company) — Investor
- 1,538,462 (number) — Number of ordinary shares
- $3.25 (dollar_amount) — Purchase price per share
- June 4, 2024 (date) — Expected closing date
- $5 million (dollar_amount) — Gross proceeds
FAQ
What is the purpose of the $5 million raised by Enlivex Therapeutics?
The filing states the company entered into a definitive agreement for a private placement, implying the funds will be used for general corporate purposes and to advance its operations, though specific use is not detailed.
Who is the institutional investor participating in the private placement?
The filing identifies the investor as a 'single healthcare-focused institutional investor' but does not disclose its specific name.
When is the private placement expected to close?
The closing of the private placement is expected to occur on or about June 4, 2024.
What is the total number of ordinary shares Enlivex Therapeutics will issue?
Enlivex Therapeutics will issue approximately 1,538,462 ordinary shares as part of this private placement.
What was Enlivex Therapeutics' former company name?
Enlivex Therapeutics Ltd. was formerly known as Bioblast Pharma Ltd., with a name change occurring on September 19, 2016.
Filing Stats: 344 words · 1 min read · ~1 pages · Grade level 11.5 · Accepted 2024-05-28 08:13:35
Key Financial Figures
- $1.40 — Ordinary Shares, at a purchase price of $1.40 per Ordinary Share (or Ordinary Share e
Filing Documents
- ea0206915-6k_enlivex.htm (6-K) — 11KB
- ea020691501ex99-1_enlivex.htm (EX-99.1) — 14KB
- 0001213900-24-046806.txt ( ) — 25KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Enlivex Therapeutics Ltd. (Registrant) By: /s/ Oren Hershkovitz Name: Oren Hershkovitz Title: Chief Executive Officer Date: May 28, 2024 2